A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time by Brooke E. Wilson, Alexandra Desnoyers, Laith Al-Showbaki, Michelle B. Nadler, Eitan Amir

Get full text

Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer by Coralea Kappel, Mitchell J. Elliott, Vikaash Kumar, Michelle B. Nadler, Alexandra Desnoyers, Eitan Amir

Get full text

Towards a Postgraduate Oncology Training Model for Family Medicine: Mixed Methods Evaluation of a Breast Oncology Rotation by Michelle B. Nadler, Brooke E. Hofbauer, Melinda Wu, Susan Hum, Christine Elser, Joyce Nyhof-Young

Get full text

Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration by Michelle B. Nadler, Brooke E. Wilson, Alexandra Desnoyers, Consolacion Molto Valiente, Ramy R. Saleh, Eitan Amir

Get full text

Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40–49 by Michelle B. Nadler, Ann Marie Corrado, Brooke E. Wilson, Alexandra Desnoyers, Eitan Amir, Noah Ivers, Laura Desveaux

Get full text

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay by Mitchell J. Elliott, Philippe Echelard, Christodoulos Pipinikas, Sasha Main, Jesús Fuentes Antrás, Aaron Dou, Zachary Veitch, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Eshetu Atenafu, Elizabeth Shah, Celeste Yu, Nathan Campbell, Robert Ventura, Lillian L. Siu, Philippe L. Bedard, Hal K. Berman, David W. Cescon

Get full text